江湖电竞手机APP下载投注
REGN
US
$
-0.02
0.00%
After Hours
$
724.30
After Hours Volume:
16.65K
| Close | Chg | Chg % |
|---|---|---|
| $724.32 | 15.47 | 2.18% |
Volume: 2.14M
65 Day Avg: 673.53K
707.25
Day Range
754.67
538.01
52 Week Range
754.67
Overview
REGN Overview
Key Data
- Open $711.73
- Day Range 707.25 - 754.67
- 52 Week Range 538.01 - 754.67
- Market Cap $77.27B
- Shares Outstanding 107.19M
- Public Float 102.55M
- Beta 0.67
- Rev. per Employee $1.372M
- P/E Ratio 14.46
- EPS $50.10
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 2.93M 08/15/22
- % of Float Shorted 2.86%
- Average Volume 673.53K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
25
Full Ratings
Recent News
Biotech and Pharma Regeneron Gets Praised by Wall Street. High-Dose Eylea Data Look ‘Strong.’
Regeneron stock price target raised to $790 from $718 at Truist
Biotech and Pharma Regeneron Stock Surges on Promising Eye Disease Drug Trial Results
Regeneron stock price target raised to $760 from $635 at Evercore ISI
Regeneron says Eylea met the primary endpoints in two trials
Regeneron Pharmaceuticals Inc. said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in a pair of pivotal trials. Regenero...
Regeneron stock to resume trading at 9:50 a.m. ET
Regeneron aflibercept 8 diabetic macular edema treatment meets primary endpoints in 2 trials
Regeneron's stock was little changed premarket prior to trading halt
Regeneron stock halted for news pending
Regeneron tops earnings expectations amid 'record' sales of several products
Regeneron Pharmaceuticals Inc. topped expectations with its second-quarter financial results Wednesday morning, though revenue and profits both fell from a year earlier. The company logged net income of $852 million, or $...
Regeneron Q2 revenue $2.86 bln vs. $5.14 bln a year ago; FactSet consensus $2.79 bln
Regeneron Q2 adj. EPS $9.77; FactSet consensus $8.62
Regeneron Q2 EPS $7.47 vs. $27.97 a year ago
9 Analysts Have This to Say About Regeneron Pharmaceuticals
on Benzinga.com
Analyst Ratings for Regeneron Pharmaceuticals
on Benzinga.com
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
on Zacks.com
SVB Securities Reaffirms Their Hold Rating on Regeneron (REGN)
SVB Securities analyst David Risinger maintained a Hold rating on Regeneron (REGN - Research Report) today and set a price target of $756.00. The company's shares closed yesterday at $708.85.Risinger covers the Healthcare ...
on TipRanks.com
TipRanks Friday PreMarket Update! DMS Soars on Buyout Bid, DOCU & ZS Raise Forecasts, + More!
Today's Daily Stock Market Preview – Friday September 9th 2022 Watch the TipRanks premarket news and stay up to date on stock market news before the market opens. We touch on earnings reports, the biggest gainers & los...
on TipRanks.com
US Stock Futures Surge; Fed Speakers In Focus
on Benzinga.com
Why Regeneron Pharmaceuticals Stock Is Crushing It Today
on Motley Fool
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
on Zacks.com
Regeneron (NASDAQ:REGN) Jumps on Achieving Primary Endpoints in DME & wAMD
Regeneron shares (NASDAQ:REGN) surged today after its Aflibercept met primary endpoints in two global trials for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). Importantly, a major part of th...
on TipRanks.com
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Amgen Inc. |
|
$131.3B |
| Moderna Inc. |
|
$55.27B |
| Gilead Sciences Inc. |
|
$81.59B |
| BioNTech SE ADR |
|
$35.72B |
| Illumina Inc. |
|
$32.61B |
| Samsung Biologics Co. Ltd. |
|
₩57.72T |
| Biogen Inc. |
|
$30.18B |
| Seagen Inc. |
|
$28.15B |
| Novozymes A/S Series B |
|
kr.113.22B |